DIOL – antiparkinson drug (Phase I clinical trials), patented small molecule.
DIOL would enable a new therapeutic strategy for treating Parkinson’s disease based on neuroprotection and neuroregeneration, but not on dopamine substitution, unlike the known drugs.
Main advantages (confirmed in preclinical studies):
– alleviates PD symptoms, being at least as potent as levodopa (currently the most effective antiparkinson drug);
– protects neurons from damage (neuroprotection), stops the progression of Parkinson’s disease and recovers damaged neurons (neuroregeneration);
– doesn’t induce movement disorders (dyskinesia and fluctuations) and CNS disorders unlike levodopa and dopamine receptor agonists;
– effective in low doses (ED = 10-20 mg/kg) with low toxicity (LD50 is over 2000 mg/kg, rodents).
Thanks to its unique efficacy and safety profile, DIOL is suitable for long-term use both as a monotherapy (replacing levodopa) and in combination with other drugs, even in early stages of Parkinson’s disease.
Market: $5 B/year (2018), expected to grow to $10 B/year by 2025.
IP: US, EU, Russian patents.
Current status: API and dosage form are developed. Preclinical studies are completed. Phase I clinical trial will be completed in May 2020.
2020 – opening a subsidiary company in the EU or the USA for the project commercialization;
2020-2022 – Phase II clinical trials (EU, USA);
2023-2025 – Phase III clinical trials (EU, USA);
2023-2025 – Project sale to a Pharma company.